Stephen F. Betz, Chief Scientific Officer at Crinetics Pharmaceuticals, Inc. (CRNX), sold 10,612 shares at $37.11 ($397K) on 2026-03-16, disclosed to the SEC on 2026-03-18.
Scheduled sale ($397k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $37.11 | 6,371 | $236K | 59.6% |
| 2 | $37.77 | 4,241 | $160K | 40.4% |
| Total | $37.37 avg | 10,612 | $397K | 100% |
| Filing → |
| CRNX | SELL | 2024-09-12 | $107K | — | Filing → |
| CRNX | SELL | 2024-08-28 | $160K | — | Filing → |
| CRNX | SELL | 2024-08-14 | $143K | — | Filing → |